REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
13/03/2026
Voltar para busca
Dado oficial do USPTO
BAXALTA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
14/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 41
Data de depósito
12/05/2015
Data de registro
22/11/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/02/2023
Última transação
14/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
Bannockburn, IL, US
Examinador
BLANDU, FLORENTINA
Unidade examinadora
M80
Descrição da marca
The mark consists of the word "BAXALTA" with light rays emanating from the center of the letter "X".
Titulares e representantes
Titulares
B. I. (pessoa física)
Representantes
A. Tally Eitan Gornitzky & Co
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 41
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationssubstances and products for the treatment of blood diseases and disordersimmuno deficiency disorderscancer; pharmaceuticals for the treatment of blood diseases and disordersimmuno deficiency disorderscancer; pharmaceutical preparationsproteinase inhibitors in the nature of alpha-1 proteinase inhibitors; pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersall containing immune globulin infusion (human) and recombinant human hyaluronidase; reconstitution assembly sold containing vials prefilled with pharmaceutical preparations for the treatment of blood diseases and disorders; normal serum albumin (human) solution for intravenous administration; immunoglobulin for parenteralintramuscular and intravenous administration to humans; antihemophilic factor for intravenous administration in humans; antihemophilic factor recombinant; pharmaceutical preparationschemotherapeutic agents
Classe 10
Medical devicesdevices for reconstituting dried pharmaceuticals; medical apparatus and instrumentsmedical infusion set for subcutaneous delivery of pharmaceuticals; medical apparatus for the preparation and parental infusion of pharmaceutical preparations
Classe 41
Education and training servicesproviding classesseminarsconferenceslectures and workshops in the fields of pharmaceuticalshealth carehealth insurancemedical informationbleeding disorders or conditionshemophiliahematologyimmunologyoncology and patient care; education servicesproviding printed publications in the nature of newsletters and white papers in the field of hemophilia; provision of information for training and teaching relating to pharmaceuticalshealth carehealth insurancemedical informationbleeding disorders or conditionshemophiliahematologyimmunologyoncology and patient care; provision of non-downloadable electronic publicationsnewslettersarticlesbrochures and booklets in the field of pharmaceuticalshealth carehealth insurancemedical informationbleeding disorders or conditionshemophiliahematologyimmunologyoncology and patient care
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
RNWL
INTERNATIONAL REGISTRATION RENEWED
06/03/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/02/2025
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
20/11/2023
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
26/10/2023
INPC
INVALIDATION PROCESSED
26/10/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
24/10/2023
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
24/02/2023
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
24/02/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/02/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/10/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/10/2022
ES71
TEAS SECTION 71 RECEIVED
22/08/2022
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
22/11/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
25/03/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/03/2017
FIMP
FINAL DISPOSITION PROCESSED
07/03/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
22/02/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
22/11/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/09/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/09/2016
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
01/07/2016
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
16/03/2016
CHPB
POST PUBLICATION AMENDMENT - ENTERED
16/02/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/02/2016
PUBO
PUBLISHED FOR OPPOSITION
16/02/2016
GPNX
NOTIFICATION PROCESSED BY IB
13/02/2016
APET
ASSIGNED TO PETITION STAFF
05/02/2016
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/01/2016
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
27/01/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/01/2016
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
18/01/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/01/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/01/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/12/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/12/2015
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
18/12/2015
ALIE
ASSIGNED TO LIE
18/12/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/12/2015
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
19/11/2015
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
19/11/2015
RFNT
REFUSAL PROCESSED BY IB
25/09/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/09/2015
RFRR
REFUSAL PROCESSED BY MPU
08/09/2015
MAFR
APPLICATION FILING RECEIPT MAILED
08/09/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/09/2015
CNRT
NON-FINAL ACTION WRITTEN
05/09/2015
DOCK
ASSIGNED TO EXAMINER
02/09/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/09/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
27/08/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BAXALTA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.